Gregory Gene Freitag - Jun 1, 2023 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role
Director
Signature
/s/Gregory Freitag
Stock symbol
AXGN
Transactions as of
Jun 1, 2023
Transactions value $
-$365,780
Form type
4
Date filed
6/5/2023, 06:47 PM
Previous filing
Jul 18, 2024
Next filing
Jul 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Sale -$108K -12.5K -3.76% $8.65 320K Jun 1, 2023 Direct F1
transaction AXGN Common Stock Sale -$258K -29.5K -9.22% $8.74 290K Jun 1, 2023 Direct F2
transaction AXGN Common Stock Options Exercise $0 +6.46K +2.23% $0.00 297K Jun 1, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Restricted Stock Units Options Exercise $0 -6.46K -100% $0.00* 0 Jun 1, 2023 Common Stock 6.46K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.57 to $8.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 This reflects the number of restricted stock units that vested on June 1, 2023.
F4 Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F5 Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date.